Kymera Therapeutics(KYMR) GlobeNewswire·2025-05-09 11:00Core Insights - Kymera Therapeutics is advancing its first-in-class pipeline aimed at treating complex immuno-inflammatory diseases, with significant progress expected in the near term [2] - The company has completed the Phase 1 healthy volunteer trial for KT-621 and initiated the KT-621 BroADen Phase 1b trial in atopic dermatitis, with data expected in late 2025 [1][2][7] - Kymera has introduced KT-579, an oral IRF5 degrader program, which is set to enter Phase 1 clinical trials in early 2026 [1][4] - A strategic decision was made to not advance KT-295 into further clinical development, allowing for a focus on the STAT6 program and extending the cash runway into the first half of 2028 [1][2][16] Business Highlights - The KT-621 program targets Th2 inflammation and has shown dupilumab-like activity in preclinical studies, with potential applications for over 130 million patients globally suffering from Th2 diseases [3] - KT-579 is positioned as a novel mechanism for treating diseases with high unmet needs, such as lupus and rheumatoid arthritis, and is expected to enter clinical testing in early 2026 [4] - Ongoing Phase 2b trials for KT-474 in partnership with Sanofi are expected to complete in 2026, further validating Kymera's innovative approach to oral degrader medicines [8] Financial Results - Collaboration revenues for Q1 2025 were 10.3 million in Q1 2024, primarily due to the Sanofi collaboration [9] - Research and development expenses rose to 48.8 million in Q1 2024, reflecting increased investment in the STAT6 and TYK2 programs [10] - The net loss for Q1 2025 was 48.6 million in Q1 2024, with cash reserves of $775 million expected to sustain operations into the first half of 2028 [12][22]